Americana Partners LLC Purchases 4,875 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Americana Partners LLC raised its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 26.1% during the fourth quarter, Holdings Channel reports. The fund owned 23,525 shares of the company’s stock after acquiring an additional 4,875 shares during the period. Americana Partners LLC’s holdings in PROCEPT BioRobotics were worth $1,894,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Rhumbline Advisers lifted its stake in shares of PROCEPT BioRobotics by 5.6% in the 4th quarter. Rhumbline Advisers now owns 61,296 shares of the company’s stock worth $4,936,000 after purchasing an additional 3,242 shares during the period. Allspring Global Investments Holdings LLC raised its position in PROCEPT BioRobotics by 218.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 401,210 shares of the company’s stock worth $33,350,000 after acquiring an additional 275,071 shares during the period. Matisse Capital boosted its stake in shares of PROCEPT BioRobotics by 112.9% during the 4th quarter. Matisse Capital now owns 22,285 shares of the company’s stock worth $1,794,000 after acquiring an additional 11,817 shares during the last quarter. Chicago Capital LLC grew its position in shares of PROCEPT BioRobotics by 44.5% during the 4th quarter. Chicago Capital LLC now owns 379,582 shares of the company’s stock valued at $30,564,000 after acquiring an additional 116,931 shares during the period. Finally, KBC Group NV increased its stake in shares of PROCEPT BioRobotics by 46.0% in the 4th quarter. KBC Group NV now owns 2,236 shares of the company’s stock worth $180,000 after purchasing an additional 705 shares in the last quarter. 89.46% of the stock is owned by hedge funds and other institutional investors.

PROCEPT BioRobotics Trading Down 2.4 %

PROCEPT BioRobotics stock opened at $67.61 on Tuesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. The firm’s 50 day moving average price is $78.51 and its 200-day moving average price is $79.80. PROCEPT BioRobotics Co. has a 1 year low of $45.20 and a 1 year high of $103.81. The stock has a market cap of $3.53 billion, a P/E ratio of -34.67 and a beta of 1.03.

Insider Buying and Selling at PROCEPT BioRobotics

In related news, EVP Alaleh Nouri sold 28,092 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $97.13, for a total value of $2,728,575.96. Following the completion of the transaction, the executive vice president now directly owns 52,472 shares of the company’s stock, valued at approximately $5,096,605.36. This trade represents a 34.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Reza Zadno sold 26,423 shares of the company’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $97.22, for a total transaction of $2,568,844.06. Following the sale, the chief executive officer now directly owns 152,762 shares in the company, valued at approximately $14,851,521.64. The trade was a 14.75 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 107,355 shares of company stock worth $10,327,788. Insiders own 17.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on PRCT shares. Jefferies Financial Group assumed coverage on PROCEPT BioRobotics in a report on Thursday, November 14th. They set a “hold” rating and a $95.00 price target for the company. Wells Fargo & Company reiterated an “overweight” rating and set a $112.00 price objective on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. Morgan Stanley assumed coverage on shares of PROCEPT BioRobotics in a research note on Monday, December 2nd. They set an “overweight” rating and a $105.00 target price on the stock. Finally, Truist Financial reiterated a “buy” rating and issued a $105.00 price target (up from $95.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, October 30th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $97.86.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).